Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 38

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 38
---
 currently be and have been a registered or beneficial owner of at least one share of the company for at least 2 years before the date of signing the proposal.   If the proposal and a written statement in support of the proposal (if any) are submitted at least three months before the anniversary date of the previous annual meeting and the proposal and written statement (if any) meet other specified requirements, then the company must either set out the proposal, including the names and mailing addresses of the submitting person and supporters and the written statement (if any), in the proxy circular of the company or attach the proposal and written statement thereto.   In certain circumstances, the company may refuse to process a proposal. |

<div align='center'>23

PLAN OF DISTRIBUTION</div>

The 17,016,694 common shares
being offered by the selling shareholders pursuant to this prospectus consists of (i) 16,970,241 common shares being offered by the CLA
Investors who are named as selling shareholders in the registration statement to which this prospectus relates, such number determined
as if Promissory Notes in the aggregate principal amount of $2.5 million were issued under the SPA and were converted into Note Shares
in full, without regard to any limitations on the issuance of Promissory Notes or on the conversion of the Promissory Notes, and (ii)
46,453 common shares that were issued to certain selling shareholders as equity award grants outside of the Plan. We will not receive any
of the proceeds from the sale by the selling shareholders of the common shares. Selling shareholders will receive all of the proceeds
from the sale of any common shares sold by it pursuant to this prospectus.

On September 17, 2025, we
entered into the SPAs with the CLA Investors. The SPAs provide that, upon the terms and subject to the conditions set forth therein, we
shall issue and sell, or have the right to issue and sell, in our sole discretion, to CLA Investors, as provided therein, convertible
notes in the aggregate principal amount of $2.5 million, for an aggregate purchase price of $2.250 million (90% of the Subscription Amount).
On the First Initial Closing, the CLA Investors purchased from us the First Initial Promissory Notes. Subject to the conditions in the
SPAs, on the date on which the registration statement pursuant to which this prospectus relates is declared effective by the SEC, we shall
issue and sell to the CL